secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001641172-25-009286
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate Q1 net loss $3.8M, cash $9.5M; NDA submission for CTx-1301 on track mid-2025
--------------------------------------------------------------------------------

- Net loss of $3.8M ($1.04 per share) for Q1 2025, compared to $3.0M in Q1 2024.
- Cash and equivalents $9.5M at March 31, 2025; cash runway into Q4 2025 beyond NDA submission.
- Pre-NDA meeting with FDA completed April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.
- Received $3M non-dilutive grant from private foundation to accelerate CTx-2103 (buspirone) anxiety asset.
- Working capital $4.9M at Q1 end, down from $7.7M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000164117225009286/0001641172-25-009286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000164117225009286/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer